{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-016712","form_type":"8-K","ticker":null,"cik":"0001840748","company_name":"LAVA Therapeutics NV","filed_at":"2025-02-25T23:59:59+00:00","discovered_at":"2026-05-14T18:03:05.220399+00:00","generated_at":"2026-05-26T04:56:46.238136+00:00","sec_items":["2.05","7.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"LAVA Therapeutics cuts workforce ~30%, starts strategic review with advisor","bullets":["Workforce reduction of approx. 30%; expects $0.5M one-time costs, mostly Q1 2025.","Board initiated strategic review to evaluate sale, merger, licensing, or other options.","Cash, cash equivalents & investments $76.6M as of Dec 31, 2024 (unaudited).","Will continue Phase 1 LAVA-1266 trial in AML/MDS and support Pfizer, J&J partnerships."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-016712","json":"https://secwatch.observer/filing/0001104659-25-016712.json","markdown":"https://secwatch.observer/filing/0001104659-25-016712.md","text":"https://secwatch.observer/filing/0001104659-25-016712.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1840748/000110465925016712/0001104659-25-016712-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1840748/000110465925016712/tm257490d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-26T04:56:46.238136+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"e341edd7f36e40460520e5447c78afc99b790645","claim":"LAVA Therapeutics NV announced a restructuring with charges of approximately $0.5 million (approximately 30%).","evidence_excerpt":"On February 20, 2025, LAVA Therapeutics N.V. (the “Company”) adopted a restructuring plan to extend its capital resources in connection with initiating a process to evaluate strategic alternatives. As part of the restructuring plan, the Company is planning a workforce reduction of approximately 30%. The Company anticipates that the reduction in workforce will be completed by July 31, 2025. The Company estimates that it will incur approximately $0.5 million of one-time termination benefits and related taxes related to the workforce reduction, with the majority of such costs to be incurred in the first quarter of 2025.","evidence_source":"SEC 8-K Item 2.05/2.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1840748/000110465925016712/0001104659-25-016712-index.htm","confidence":0.9,"family_label":"Restructurings & Charges","details":[{"label":"Type","value":"restructuring"},{"label":"Charge","value":"approximately $0.5 million"},{"label":"Headcount","value":"approximately 30%"}],"fact_type":"restructuring_charge"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}